Abstract
The ability of tumor-reactive T cells to mediate in vivo tumor regression has been demonstrated in murine tumor models and by the clinical responses to adoptive immunotherapy with tumor-infiltrating lymphocytes isolated from human melanomas. Investigations carried out in the past several years have resulted in the isolation of a number of the genes encoding antigens recognized by melanoma-reactive T cells. The ability of these products to serve as tumor regression antigens has now begun to be evaluated in clinical vaccine trials.
| Original language | English |
|---|---|
| Pages (from-to) | 628-636 |
| Number of pages | 9 |
| Journal | Current Opinion in Immunology |
| Volume | 8 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 1996 Oct |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Fingerprint
Dive into the research topics of 'Human tumor antigens recognized by T cells'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS